SCHEMBL22905486

SCHEMBL22905486

CNc1c2c(c(C#N)c3c1CCC3)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.39
KDM4E B2RXH2 9/20 0.39
GAA P10253 3/20 0.39
RXFP1 Q9HBX9 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
HPGD P15428 8/20 0.37
HIF1A Q16665 1/20 0.37
KMT2A Q03164 4/20 0.36
HTT P42858 3/20 0.36
GLA P06280 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
POLB P06746 3/20 0.35
MEN1 O00255 3/20 0.35
MAPT P10636 2/20 0.35
CASP1 P29466 2/20 0.35
HSD17B10 Q99714 2/20 0.35
PABPC1 P11940 1/20 0.35
RECQL P46063 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22013537 0.76 MEN1 (0.54) ALDH1A1KDM4EGAAHPGDKMT2A
SCHEMBL22705368 0.75 ALDH1A1 (0.33) ALDH1A1KDM4EGAARXFP1APOBEC3G
SCHEMBL24592537 0.75 ALDH1A1 (0.37) ALDH1A1KDM4EGAARXFP1APOBEC3G
SCHEMBL22705075 0.75 KMT2A (0.42) ALDH1A1KDM4EGAARXFP1APOBEC3G
SCHEMBL22011764 0.75 ALDH1A1 (0.47) ALDH1A1KDM4EGAARXFP1APOBEC3G
SCHEMBL21962721 0.74 ALDH1A1 (0.41) ALDH1A1KDM4EGAAHPGDKMT2A
SCHEMBL9748738 0.73 MAPK1 (0.45) ALDH1A1KDM4EGAARXFP1APOBEC3G
SCHEMBL22012481 0.72 POLB (0.40) ALDH1A1KDM4EGAAHPGDKMT2A
SCHEMBL21586419 0.72 CYP1A2 (0.30) GAAPOLB
SCHEMBL22827696 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021009566-A1 N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) ZOMAGEN BIOSCIENCES LTD (US) 2021-01-21 WO disclosed